aurx目前正在寻求1000万美元的投资，以便进入大规模生产。
This may be a single investment or a combination of many.
这可能是一个单一的投资或结合很多。
Please contact our staff at customerservice@aurx.com for more information.
请联络我们的工作人员在
customerservice@aurx.com以获取更多信息。
This investment will allow AuRx Inc. to build and operate a production plant.
这项投资将使aurx公司，以兴建及经营一个生产厂。
Production and sales will coincide with the Phase 3 clinical trial which we have been authorized to begin.
生产和销售将与第三期临床试验，我们已被授权开始。
Newest Press Release: September 2006
最新新闻发布： 2006年9月 
Skip directly to our latest press releases by clicking here or the "Management" button.
直接跳到我们最新的新闻发布点击这里还是"管理"按钮。 Our Clinical Trial Registry gives you a way of receiving direct information about upcoming trials, press releases and other pertinent information about the therapy.
我们的临床试验登记给你的一种方式获得直接信息约即将进行的审判，新闻稿和其他有关资料对治疗。
The registry also gives AuRx a database needed in our efforts to secure funding to continue the clinical trials.
书记官也给aurx一个数据库，需要我们努力争取资金，以继续进行临床试验。
The registry form is transmitted on a secure page, shown by the lock icon at the bottom of your screen and the “S” in the “https” in the web address.
登记表格传送到一个安全页，显示锁定图标，在底部你的屏幕和的" s " ，在" https " ，在网络地址。
Access to your information is very tightly controlled and extremely limited ensuring your confidentiality.
进入你的资料是非常严格控制和极其有限的，确保您的机密性。
Thank you for registering!
感谢您的注册！
Sign up for our Clinical Trial Registry!
签约为我们的临床试验登记！ A comparison between the best currently available treatment for genital herpes, Valtrex (data taken from package insert), and the AuRx immunotherapy.
对比最佳现有的治疗生殖器疱疹， valtrex （数据取自说明书） ，以及aurx免疫治疗。
There are a number of differences in the patients enrolled in the trials.
有若干的差异，在患者就读于审判。
1.
1 。
For valaciclovir, recurrences were scored only for patients having lesions, whereas for AuRx, recurrences were scored on the basis of any sign or symptom.
为万乃洛韦，复发得分只为患者有无病变，而aurx ，复发的基础上取得的任何迹象或征兆。
2.
2 。
For valaciclovir, the patients enrolled had a median of 5 outbreaks per year, whereas the patients in the AuRx study had an average of 9 outbreaks, with a minimum of 5 per year.
为万乃洛韦，病人参加了中位数为5暴发每一年，而病人在aurx研究了平均9暴发，至少5名左右。
The valaciclovir study results were 25% less effective for patients having more than 10 recurrences per year.
该伐昔洛韦的研究成果，分别为25 ％ ，效果较差的病人有10多复发左右。
3.
3 。
For valaciclovir, the percentage of patients having a placebo effect was much lower than for the AuRx study.
为万乃洛韦，百分比例安慰剂效应远低于为aurx研究。
4.
4 。
The dose of the AuRx immunotherapy has not been optimized, whereas the valaciclovir studies were done over a period more than ten years and designed for optimizing the dose and treatment schedule.
该剂量的aurx免疫疗法并没有得到优化，而万乃洛韦研究，做了近一个时期以来已有十多年，并设计了优化剂量和治疗如期进行。
